Synopsis
Synopsis
0
KDMF
0
VMF
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Belustine
2. Ccnu
3. Cecenu
4. Ceenu
5. Nsc 79037
6. Nsc-79037
7. Nsc79037
1. 13010-47-4
2. 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea
3. Ccnu
4. Belustine
5. Ceenu
6. Cecenu
7. Cinu
8. Chloroethylcyclohexylnitrosourea
9. Urea, N-(2-chloroethyl)-n'-cyclohexyl-n-nitroso-
10. Lomustina
11. Lomustinum
12. Lomustinum [inn-latin]
13. Lomustina [inn-spanish]
14. N-(2-chloroethyl)-n'-cyclohexyl-n-nitrosourea
15. 1-(2-chloroethyl)-3-cyclohexylnitrosourea
16. Nsc 79037
17. Nsc-79037
18. Gleostine
19. Cyclohexyl Chloroethyl Nitrosourea
20. Sri 2200
21. Icig 1109
22. Nci-c04740
23. (chloro-2-ethyl)-1-cyclohexyl-3-nitrosourea
24. Rb 1509
25. (cloro-2-etil)-1-cicloesil-3-nitrosourea
26. Nsc79037
27. Lomustine (ceenu)
28. 1-nitrosourea, 1-(2-chloroethyl)-3-cyclohexyl-
29. Chebi:6520
30. Urea, 1-(2-chloroethyl)-3-cyclohexyl-1-nitroso-
31. Ccn-u
32. 7brf0z81kg
33. Ccnu; Nsc 79037
34. 1-(2-chloroethyl)-3-cyclohexyl-1-nitroso-urea
35. Ncgc00167466-01
36. Dsstox_cid_3222
37. 3-(2-chloroethyl)-1-cyclohexyl-3-nitrosourea
38. Dsstox_rid_76930
39. Dsstox_gsid_23222
40. Ccris 860
41. Cas-13010-47-4
42. Ccnu [chloroethyl Nitrosoureas]
43. Hsdb 6519
44. Sr-05000001497
45. Einecs 235-859-2
46. Unii-7brf0z81kg
47. Brn 2125058
48. (cloro-2-etil)-1-cicloesil-3-nitrosourea [italian]
49. Lomustine [usan:inn:ban]
50. Ai3-52779
51. Gleostine (tn)
52. Lomustine- Bio-x
53. Lomustine, >=98%
54. Lomustine (usp/inn)
55. Lomustine [inn]
56. Lomustine [mi]
57. Lomustine [hsdb]
58. Lomustine [usan]
59. Lomustine [vandf]
60. 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea [chloroethyl Nitrosoureas]
61. Chembl514
62. Lomustine [mart.]
63. Ncimech_000220
64. Lomustine [usp-rs]
65. Lomustine [who-dd]
66. Schembl3995
67. Wln: L6tj Amvnno&2g
68. Gtpl7214
69. Lomustine [orange Book]
70. Dtxsid2023222
71. Lomustine [ep Monograph]
72. Lomustine [usp Monograph]
73. Hms2090a17
74. Hms3655i16
75. Pharmakon1600-01502301
76. Bcp06551
77. Zinc3831006
78. Tox21_112470
79. Bdbm50247919
80. Mfcd00012392
81. Nsc759635
82. S1840
83. Akos005766022
84. Tox21_112470_1
85. Ac-8062
86. Ccg-213022
87. Cs-1461
88. Db01206
89. Ds-1269
90. Nsc-759635
91. Ncgc00167466-02
92. Ncgc00167466-03
93. Bl164634
94. Hy-13669
95. Nci60_041743
96. Db-017097
97. Am20070540
98. Ft-0627972
99. L0251
100. Sw220040-1
101. C07079
102. D00363
103. Ab00173884-02
104. Ab00173884-03
105. Ab00173884-04
106. Ab00173884_05
107. Ab00173884_06
108. 010l474
109. A806019
110. Q415378
111. Sr-05000001497-1
112. Sr-05000001497-3
113. Urea, 1-(2-chloroethyl)-3-cyclohexyl)-1-nitroso-
114. W-108355
115. Lomustine, European Pharmacopoeia (ep) Reference Standard
116. 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea [iarc]
117. Lomustine, United States Pharmacopeia (usp) Reference Standard
118. 1-(2-chloroethyl)-1-[(cyclohexylamino)carbonyl]-2-oxohydrazine #
119. 2-chloro-n-(cyclohexyl-c-hydroxycarbonimidoyl)-n-nitrosoethan-1-amine
120. 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea1-(2-chloroethyl)-3-cyclohexyl-1-nitroso-urea13010-47-4nci60_0417431-(2-chloroethyl)-3-cyclohexylnitrosourea1-nitrosourea, 1-(2-chloroethyl)-3-cyclohexyl-be
| Molecular Weight | 233.69 g/mol |
|---|---|
| Molecular Formula | C9H16ClN3O2 |
| XLogP3 | 2.8 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 3 |
| Rotatable Bond Count | 3 |
| Exact Mass | 233.0931045 g/mol |
| Monoisotopic Mass | 233.0931045 g/mol |
| Topological Polar Surface Area | 61.8 Ų |
| Heavy Atom Count | 15 |
| Formal Charge | 0 |
| Complexity | 219 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Antineoplastic Agents, Alkylating
National Library of Medicine's Medical Subject Headings online file (MeSH, 1999)
CeeNU has been shown to be useful as a single agent in addition to other treatment modalities, or in established combination therapy with other approved chemotherapeutic agents in the following: Brain tumors-both primary and metastatic, in patients who have already received appropriate surgical and/or radiotherapeutic procedures. Hodgkin's Disease-secondary therapy in combination with other approved drugs in patients who relapse while being treated with primary therapy, or who fail to respond to primary therapy. /Included in US product label/
US Natl Inst Health; DailyMed. Current Medication Information for CeeNU (lomustine) (June 2009). Available from, as of November 4, 2009: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=10860
Antineoplastic agent. The compound has had limited use since the early 1970s in the treatment of Hodgkin's disease and various solid tumors. These include primary and metastatic brain tumors, colorectal tumors, and certain pulmonary malignancies. It is usually used in conjunction with other antineoplastic drugs.
DHHS/National Toxicology Program; Eleventh Report on Carcinogens: Lomustine (1-(2-Chloroethyl)-3-Cyclohexyl-1-Nitrosourea) (13010-47-4) (January 2005). Available from, as of September 29, 2009: https://ntp.niehs.nih.gov/ntp/roc/eleventh/profiles/s035ccnu.pdf
Although lomustine is labeled for use in combination with other agents as secondary therapy for the treatment of refractory or relapsed Hodgkin's disease, combination regimens containing other agents currently are preferred for this cancer. /Included in US product label/
American Society of Health System Pharmacists; AHFS Drug Information 2009. Bethesda, MD. (2009), p. 1153
For more Therapeutic Uses (Complete) data for LOMUSTINE (8 total), please visit the HSDB record page.
/BOXED WARNING/ WARNINGS: CeeNU (lomustine) should be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. Bone marrow suppression, notably thrombocytopenia and leukopenia, which may contribute to bleeding and overwhelming infections in an already compromised patient, is the most common and severe of the toxic effects of CeeNU. Since the major toxicity is delayed bone marrow suppression, blood counts should be monitored weekly for at least 6 weeks after a dose. At the recommended dosage, courses of CeeNU should not be given more frequently than every 6 weeks. The bone marrow toxicity of CeeNU is cumulative and therefore dosage adjustment must be considered on the basis of nadir blood counts from prior dose
US Natl Inst Health; DailyMed. Current Medication Information for CeeNU (lomustine) (Updated: November 2012). Available from, as of April 24, 2015: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=17893de9-7d54-448c-9fca-d10642046d14
Because some lomustine metabolites are present in milk, women receiving the drug probably should not nurse their infants.
American Society of Health System Pharmacists; AHFS Drug Information 2009. Bethesda, MD. (2009), p. 1154
Delayed onset of pulmonary fibrosis occurring up to 17 years after treatment has been reported in patients receiving related nitrosoureas combined with cranial radiation therapy for intracranial tumors during childhood and adolescence (age 1-16 years). Late onset of reduction in pulmonary function was observed in all long-term survivors. Nitrosourea-induced pulmonary fibrosis may be slowly progressive and can cause death.
American Society of Health System Pharmacists; AHFS Drug Information 2009. Bethesda, MD. (2009), p. 1153
Nausea and vomiting occur in 45-100% of patients within 45 min to 6 hr after ingestion of an oral dose of lomustine. Although these symptoms are not severe and usually abate within 24 hr, they may persist up to 36 hr and are often followed by 2-3 days of anorexia. Stomatitis has occurred infrequently.
American Society of Health System Pharmacists; AHFS Drug Information 2009. Bethesda, MD. (2009), p. 1153
For more Drug Warnings (Complete) data for LOMUSTINE (25 total), please visit the HSDB record page.
For the treatment of primary and metastatic brain tumors as a component of combination chemotherapy in addition to appropriate surgical and/or radiotherapeutic procedures. Also used in combination with other agents as secondary therapy for the treatment of refractory or relapsed Hodgkin's disease.
Lomustine is an alkylating agent of the nitrosourea type. Lomustine and its metabolites interferes with the function of DNA and RNA. It is cell cycle–phase nonspecific. Cancers form when some cells within the body multiply uncontrollably and abnormally. These cells then spread and destroy nearby tissues. Lomustine acts by slowing this process down. It kills cancer cells by damaging the DNA (the genetic material inside the cells) and stops them from dividing.
Antineoplastic Agents, Alkylating
A class of drugs that differs from other alkylating agents used clinically in that they are monofunctional and thus unable to cross-link cellular macromolecules. Among their common properties are a requirement for metabolic activation to intermediates with antitumor efficacy and the presence in their chemical structures of N-methyl groups, that after metabolism, can covalently modify cellular DNA. The precise mechanisms by which each of these drugs acts to kill tumor cells are not completely understood. (From AMA, Drug Evaluations Annual, 1994, p2026) (See all compounds classified as Antineoplastic Agents, Alkylating.)
L - Antineoplastic and immunomodulating agents
L01 - Antineoplastic agents
L01A - Alkylating agents
L01AD - Nitrosoureas
L01AD02 - Lomustine
Absorption
Well and rapidly absorbed from the gastrointestinal tract.
Route of Elimination
Following oral administration of radioactive CeeNU at doses ranging from 30 mg/m2 to 100 mg/m2, about half of the radioactivity given was excreted in the urine in the form of degradation products within 24 hours.
Lomustine is excreted primarily in the urine as metabolites. Following oral administration of (14)C-labeled lomustine, about 50% of the radioactivity is excreted within 12 hr and about 75% within 4 days.
American Society of Health System Pharmacists; AHFS Drug Information 2009. Bethesda, MD. (2009), p. 1154
Lomustine is reported to be widely distributed. Lomustine and/or its metabolites cross the blood-brain barrier and are rapidly transported into cells due to their high lipid solubility. Although intact lomustine is not detectable in the CSF, active metabolites of the drug appear in substantial concentrations within 30 minutes after oral administration of lomustine. CSF concentrations of metabolites have been reported to be 15-50% or greater than concurrent plasma concentrations. Lomustine metabolites are present in milk, but in concentrations than those in maternal plasma.
American Society of Health System Pharmacists; AHFS Drug Information 2009. Bethesda, MD. (2009), p. 1154
Lomustine is rapidly absorbed from the GI tract; the drug is also absorbed following topical application. Peak plasma concentrations of metabolites occur within 1-6 hours following administration of an oral dose of lomustine.
American Society of Health System Pharmacists; AHFS Drug Information 2009. Bethesda, MD. (2009), p. 1154
Following its ip or iv injection or oral administration, (14)C-labelled CCNU was rapidly distributed to many tissues in mice, rats, rabbits and dogs.. About 80% of label was excreted in the urine of mice 24 hours after a single parenteral or oral dose of 50 mg/kg bw.
IARC. Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans. Geneva: World Health Organization, International Agency for Research on Cancer, 1972-PRESENT. (Multivolume work). Available at: https://monographs.iarc.fr/ENG/Classification/index.php, p. V26 142 (1981)
Hepatic. Rapid and complete, with active metabolites.
CCNU undergoes spontaneous decomposition under physiological conditions to release both alkylating and carbamoylating entities. It disappears from plasma within 5 minutes following its oral administration, but the antitumor effect of its metabolites may persist for up to 15 minutes. ... In addition to chemical decomposition, CCNU may be converted by microsomal metabolism to 6 isomeric hydroxylated derivatives, some of which may differ in their biological properties from CCNU.
IARC. Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans. Geneva: World Health Organization, International Agency for Research on Cancer, 1972-PRESENT. (Multivolume work). Available at: https://monographs.iarc.fr/ENG/Classification/index.php, p. V26 142 (1981)
Virtually all of a dose of lomustine is metabolized within 1 hour after oral administration. The half-life of lomustine metabolites is biphasic; although the initial plasma half-life is 6 hours, the second phase plasma half-life is 1-2 days, and 15-20% of the metabolites remain in the body 5 days after administration of lomustine. Prolongation of plasma concentrations is thought to reflect a combination of protein binding and enterohepatic circulation of metabolites.
American Society of Health System Pharmacists; AHFS Drug Information 2009. Bethesda, MD. (2009), p. 1154
Approximately 94 minutes, however the metabolites have a serum half-life of 16 to 48 hours.
The half-life of lomustine metabolites is biphasic; although the initial plasma half-life is 6 hours, the second phase plasma half-life is 1-2 days, and 15-20% of the metabolites remain in the body 5 days after administration of lomustine.
American Society of Health System Pharmacists; AHFS Drug Information 2009. Bethesda, MD. (2009), p. 1154
Lomustine is a highly lipophilic nitrosourea compound which undergoes hydrolysis in vivo to form reactive metabolites. These metabolites cause alkylation and cross-linking of DNA (at the O6 position of guanine-containing bases) and RNA, thus inducing cytotoxicity. Other biologic effects include inhibition of DNA synthesis and some cell cycle phase specificity. Nitrosureas generally lack cross-resistance with other alkylating agents. As lomustine is a nitrosurea, it may also inhibit several key processes such as carbamoylation and modification of cellular proteins.
Although lomustine is believed to act by alkylation, the mechanism of action has not been completely elucidated, and other effects as carbamoylation and modification of cellular proteins may be involved. The overall result is thought to be the inhibition of both DNA and RNA synthesis.
American Society of Health System Pharmacists; AHFS Drug Information 2009. Bethesda, MD. (2009), p. 1154
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CEP/COS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Related Excipient Companies
Rochem International Inc
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]SPI Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Faran Shimi Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Healthcare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pfanstiehl
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Anhui Sunhere Pharmaceutical Excipients Co.,Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Chemicals
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ingredion Pharma Solutions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kerry
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Microlex e.U
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pluviaendo
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Prachin Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Roquette
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shanghai Shenmei Pharmaceutical Technology Co., Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shijiazhuang Huaxu Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Excipients by Applications
Fillers, Diluents & Binders
Direct Compression
Chewable & Orodispersible Aids
Taste Masking
Lubricants & Glidants
Co-Processed Excipients
Parenteral
Disintegrants & Superdisintegrants
Granulation
Thickeners and Stabilizers
Emulsifying Agents
API Stability Enhancers
Controlled & Modified Release
Digital Content
DATA COMPILATION #PharmaFlow
NEWS #PharmaBuzz
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?
